Stay updated on Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial
Sign up to get notified when there's something new on the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page.

Latest updates to the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page revision was updated from v3.6.5 to v3.6.6. This reflects a small update to the page's versioning/metadata rather than substantive changes to the study content.SummaryDifference0.0%

- Check25 days agoChange DetectedThe entry 2016 ( U.S. NIH Grant/Contract ) was added to the trial's list of identifiers, indicating a U.S. NIH funding attribution. This clarifies the funding source associated with the study.SummaryDifference0.0%

- Check39 days agoChange DetectedA newer revision tag (v3.6.5) was added, replacing the previous revision (v3.6.4) for the study record, indicating an updated version of the page. This update appears to be an internal revision rather than a substantive change to the study details.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision tag on the page updated to v3.6.4, replacing v3.6.3. This indicates a minor update to the page rendering rather than changes to the study details.SummaryDifference0.0%

- Check75 days agoChange DetectedThe page revision label was updated from v3.6.2 to v3.6.3, indicating a newer deployed version of the page. This change updates the visible revision tag on the site.SummaryDifference0.0%

- Check83 days agoChange DetectedA revision tag on the page is updated to v3.6.2, replacing the previous v3.6.0, indicating a small update to the page or its underlying system.SummaryDifference0.0%

Stay in the know with updates to Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page.